NASDAQ: ADAGAdagene Inc Stock
$1.77+0.00 (+0%)
Updated May 16, 2025
ADAG Price
$1.77
Fair Value Price
$2.06
Market Cap
$83.38M
52 Week Low
$1.33
52 Week High
$3.58
P/E
-2.4x
P/B
1.65x
P/S
868.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$103.20k
Earnings
-$33.42M
Gross Margin
100%
Operating Margin
-31,578.03%
Profit Margin
-32,386.4%
Debt to Equity
0.77
Operating Cash Flow
-$30M
Beta
0.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADAG Overview
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADAG's potential to beat the market
- ADAG doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADAG
RankedUnranked of 456
RankedUnranked of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $8.19 | A | |
| $63.31 | A |
Be the first to know about important ADAG news, forecast changes, insider trades & much more!
ADAG News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADAG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADAG ($1.77) is undervalued by 13.94% relative to our estimate of its Fair Value price of $2.06 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ADAG ($1.77) is not significantly undervalued (13.94%) relative to our estimate of its Fair Value price of $2.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ADAG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADAG due diligence checks available for Premium users.
Valuation
ADAG fair value
Fair Value of ADAG stock based on Discounted Cash Flow (DCF)
Price
$1.77
Fair Value
$2.06
Undervalued by
13.94%
ADAG ($1.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADAG ($1.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADAG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADAG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.4x
Industry
-154.88x
Market
25.95x
ADAG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.65x
Industry
4.21x
ADAG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADAG's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ADAG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ADAG's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$89.3M
Liabilities
$38.7M
Debt to equity
0.77
ADAG's short-term assets ($87.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADAG's short-term assets ($87.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADAG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADAG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ADAG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADAG vs Biotech Stocks
Adagene Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.